Longivitron Overview

  • Year Founded
  • 2020

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Series A

  • Investors
  • 5

Longivitron General Information

Description

Developer of novel metabolic checkpoint biotechnology platform intended for oncology and immunology treatment industries. The company's offerings include metabolic checkpoint research platforms, immunomodulatory drug candidates, and biotechnology solutions targeting immune system pathways, thereby enabling the development therapies for cancer and immune related diseases.

Contact Information

Website
www.longivitron.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Unit 329, Building A2, Phase I Project, Biomedical Industrial Park
  • No. 218 Xinghu Street, Suzhou Industrial Park, Suzhou Area of China Pilot Free Trade Zone
  • Suzhou, Jiangsu 215000
  • China
+86 138
Primary Industry
Drug Discovery
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • Unit 329, Building A2, Phase I Project, Biomedical Industrial Park
  • No. 218 Xinghu Street, Suzhou Industrial Park, Suzhou Area of China Pilot Free Trade Zone
  • Suzhou, Jiangsu 215000
  • China
+86 138

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Longivitron Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Early Stage VC (Series A) 03-Jun-2026 Completed Clinical Trials - Phase 1
1. Early Stage VC 15-Jun-2022 Completed Clinical Trials - Phase 1
To view Longivitron’s complete valuation and funding history, request access »

Longivitron Patents

  • 17

    Total Documents Applications and Grants

  • Total Patents Families

  • 2

    Granted

  • 9

    Pending

  • Expiring in next 12 mo

Longivitron Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026092351-A1 Phenylacrylamide compound, and preparation method therefor and use thereof Pending 31-Oct-2024
EP-4527828-A1 Biphenyl compound, pharmaceutical composition, method for preparing same, and use thereof Pending 09-Jun-2022
EP-4527828-A4 Biphenyl compound, pharmaceutical composition, method for preparing same, and use thereof Pending 09-Jun-2022
US-20260297017-A1 Biphenyl compound, pharmaceutical composition, method for preparing same, and use thereof Pending 09-Jun-2022
WO-2023236924-A1 Biphenyl compound, pharmaceutical composition, method for preparing same, and use thereof Inactive 09-Jun-2022 C07C49/755
To view Longivitron’s complete patent history, request access »

Longivitron Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds
Hangzhou Tigermed Consulting Company Corporation Minority
Shenzhen Capital (Shenzhen) Growth/Expansion Minority
Leader Venture Capital Growth/Expansion Minority
Shenzhen Capital Group Venture Capital Minority
Suzhou Junshang Investment Management Growth/Expansion Minority
To view Longivitron’s complete investors history, request access »

Ready to get started?

Request a free trial

Longivitron FAQs

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process